HRP20210838T1 - Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe - Google Patents
Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe Download PDFInfo
- Publication number
- HRP20210838T1 HRP20210838T1 HRP20210838TT HRP20210838T HRP20210838T1 HR P20210838 T1 HRP20210838 T1 HR P20210838T1 HR P20210838T T HRP20210838T T HR P20210838TT HR P20210838 T HRP20210838 T HR P20210838T HR P20210838 T1 HRP20210838 T1 HR P20210838T1
- Authority
- HR
- Croatia
- Prior art keywords
- lymphoma
- combination according
- hodgkin
- seq
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196184 | 2016-10-28 | ||
| EP17797564.6A EP3532098B1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| PCT/EP2017/077654 WO2018078123A1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210838T1 true HRP20210838T1 (hr) | 2021-08-06 |
Family
ID=57218739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210838TT HRP20210838T1 (hr) | 2016-10-28 | 2017-10-27 | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12358983B2 (enExample) |
| EP (2) | EP3903821A1 (enExample) |
| JP (3) | JP7094950B2 (enExample) |
| KR (2) | KR102500868B1 (enExample) |
| CN (2) | CN109890418B (enExample) |
| AU (2) | AU2017348624B2 (enExample) |
| BR (1) | BR112019008244A2 (enExample) |
| CA (1) | CA3037246A1 (enExample) |
| CY (1) | CY1124648T1 (enExample) |
| DK (1) | DK3532098T3 (enExample) |
| ES (1) | ES2871574T3 (enExample) |
| HR (1) | HRP20210838T1 (enExample) |
| HU (1) | HUE054496T2 (enExample) |
| IL (3) | IL320372A (enExample) |
| LT (1) | LT3532098T (enExample) |
| MX (2) | MX2019004942A (enExample) |
| PL (1) | PL3532098T3 (enExample) |
| PT (1) | PT3532098T (enExample) |
| RS (1) | RS62036B1 (enExample) |
| RU (1) | RU2756405C2 (enExample) |
| SG (1) | SG10202104036QA (enExample) |
| SI (1) | SI3532098T1 (enExample) |
| SM (1) | SMT202100347T1 (enExample) |
| WO (1) | WO2018078123A1 (enExample) |
| ZA (1) | ZA201903302B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| LT3630177T (lt) * | 2017-05-31 | 2023-10-25 | Morphosys Ag | Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| ES3037206T3 (en) * | 2018-08-31 | 2025-09-30 | Adc Therapeutics Sa | Combination therapy |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| KR20220104176A (ko) * | 2019-10-31 | 2022-07-26 | 모르포시스 아게 | 순차적 항-cd19 요법 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| ATE552204T1 (de) | 2006-08-15 | 2012-04-15 | Hydralift Amclyde Inc | Direkt wirkender einzelscheiben-aktiv/passiv- hubkompensator |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| EP2176298B1 (en) * | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| US20100128586A1 (en) | 2008-11-25 | 2010-05-27 | Mediatek Inc. | Method and apparatus for accessing data from disc with linking area |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2010263272C1 (en) | 2009-06-24 | 2016-02-11 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| US8549399B2 (en) | 2011-01-18 | 2013-10-01 | Apple Inc. | Identifying a selection of content in a structured document |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| HRP20220224T1 (hr) | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
| KR20140064873A (ko) | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| EP3476392A1 (en) * | 2014-02-28 | 2019-05-01 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| AU2015244039B2 (en) * | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| AU2015277516A1 (en) | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| MX392487B (es) | 2014-10-20 | 2025-03-21 | Juno Therapeutics Inc | Métodos y composiciones para dosificación en terapia celular adoptiva. |
| CN107406507A (zh) * | 2015-02-12 | 2017-11-28 | 西雅图基因公司 | 使用cd19‑adc和长春新碱的组合疗法 |
| PE20180454A1 (es) | 2015-05-26 | 2018-03-05 | Hoffmann La Roche | Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2 |
| LT3302550T (lt) | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| FI3916392T3 (fi) | 2016-05-30 | 2024-06-03 | Incyte Corp | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla |
| WO2018002031A1 (en) | 2016-06-27 | 2018-01-04 | Morphosys Ag | Anti-cd19 antibody formulations |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| LT3630177T (lt) | 2017-05-31 | 2023-10-25 | Morphosys Ag | Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu |
| US20210292410A1 (en) | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| AU2020267823A1 (en) | 2019-05-03 | 2021-11-11 | Incyte Corporation | Anti-CD19 therapy in patients having a limited number of NK cells |
| CN115151565A (zh) | 2019-10-31 | 2022-10-04 | 莫佛塞斯公司 | 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法 |
| TW202525340A (zh) | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| KR20220104176A (ko) | 2019-10-31 | 2022-07-26 | 모르포시스 아게 | 순차적 항-cd19 요법 |
| WO2021259902A1 (en) | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint |
| WO2022117799A2 (en) | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
| CA3255552A1 (en) | 2021-12-22 | 2023-06-29 | Incyte Corporation | TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY |
-
2017
- 2017-10-27 US US16/342,645 patent/US12358983B2/en active Active
- 2017-10-27 RU RU2019113370A patent/RU2756405C2/ru active
- 2017-10-27 SM SM20210347T patent/SMT202100347T1/it unknown
- 2017-10-27 CN CN201780067047.1A patent/CN109890418B/zh active Active
- 2017-10-27 WO PCT/EP2017/077654 patent/WO2018078123A1/en not_active Ceased
- 2017-10-27 IL IL320372A patent/IL320372A/en unknown
- 2017-10-27 AU AU2017348624A patent/AU2017348624B2/en active Active
- 2017-10-27 ES ES17797564T patent/ES2871574T3/es active Active
- 2017-10-27 SG SG10202104036QA patent/SG10202104036QA/en unknown
- 2017-10-27 PT PT177975646T patent/PT3532098T/pt unknown
- 2017-10-27 RS RS20210792A patent/RS62036B1/sr unknown
- 2017-10-27 KR KR1020197012532A patent/KR102500868B1/ko active Active
- 2017-10-27 DK DK17797564.6T patent/DK3532098T3/da active
- 2017-10-27 CN CN202410183851.8A patent/CN118045175A/zh active Pending
- 2017-10-27 EP EP21165598.0A patent/EP3903821A1/en active Pending
- 2017-10-27 CA CA3037246A patent/CA3037246A1/en active Pending
- 2017-10-27 IL IL301786A patent/IL301786B2/en unknown
- 2017-10-27 PL PL17797564T patent/PL3532098T3/pl unknown
- 2017-10-27 IL IL266216A patent/IL266216B2/en unknown
- 2017-10-27 JP JP2019522273A patent/JP7094950B2/ja active Active
- 2017-10-27 KR KR1020237005018A patent/KR20230028571A/ko not_active Ceased
- 2017-10-27 EP EP17797564.6A patent/EP3532098B1/en active Active
- 2017-10-27 MX MX2019004942A patent/MX2019004942A/es unknown
- 2017-10-27 LT LTEP17797564.6T patent/LT3532098T/lt unknown
- 2017-10-27 SI SI201730811T patent/SI3532098T1/sl unknown
- 2017-10-27 BR BR112019008244-1A patent/BR112019008244A2/pt unknown
- 2017-10-27 HR HRP20210838TT patent/HRP20210838T1/hr unknown
- 2017-10-27 HU HUE17797564A patent/HUE054496T2/hu unknown
-
2019
- 2019-04-26 MX MX2022016270A patent/MX2022016270A/es unknown
- 2019-05-24 ZA ZA2019/03302A patent/ZA201903302B/en unknown
-
2021
- 2021-06-10 CY CY20211100512T patent/CY1124648T1/el unknown
-
2022
- 2022-06-22 JP JP2022100006A patent/JP2022137089A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125584A patent/JP2024167208A/ja active Pending
- 2024-12-23 AU AU2024287178A patent/AU2024287178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210838T1 (hr) | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe | |
| HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
| HRP20211291T1 (hr) | Kombinacije i njihove primjene | |
| JP2019533682A5 (enExample) | ||
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| JP2017507954A5 (enExample) | ||
| JP2017048208A5 (enExample) | ||
| HRP20231021T1 (hr) | Protutijela anti-cd38 za liječenje akutne limfoblastične leukemije | |
| JP2017528462A5 (enExample) | ||
| JP2023093495A5 (enExample) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| RU2016147523A (ru) | Лечение гиперкинетических двигательных расстройств | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| RU2015110981A (ru) | Комбинации и их применение | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| PE20200721A1 (es) | Conjugados de farmaco-anticuerpo (adc) anti-egfr y sus usos | |
| RU2018125622A (ru) | Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза | |
| HRP20231229T1 (hr) | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje | |
| WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |